Scientists have finally unlocked nature's secret for building better cancer drugs, offering a promising avenue for developing new treatments for hard-to-treat cancers. This groundbreaking discovery, published in Nature Communications, reveals how bacteria naturally manufacture multiple versions of powerful cancer drugs, a mystery that has long puzzled researchers.
For decades, the potential of bacterial enzymes to create new drug variants through combinatorial biosynthesis has been recognized, but progress was hindered by a lack of understanding of how these enzymes coordinate their work. The new study, led by Dr. Munro Passmore, has identified the natural "mix and match" system that bacteria use to produce a family of closely related anti-cancer compounds, including Romidepsin (Istodax), an FDA-approved treatment for certain blood cancers.
The key to this discovery lies in the role of small molecular regions called 'docking domains'. These domains act as connectors between the core drug-building machinery and the enzymes responsible for adding different components. By sharing a conserved connection point, these docking domains enable bacteria to interact with multiple enzyme partners, allowing for the creation of a variety of related drug molecules while maintaining the precision needed for their effectiveness.
The researchers also shed light on the evolutionary history of these natural drug-producing systems. They suggest that the newly identified compound likely evolved from a related drug-producing pathway through gene duplication and recombination over time. This understanding provides a blueprint for scientists to reverse-engineer nature's evolutionary logic, enabling the design of synthetic pathways that can generate new anti-cancer drug candidates with optimized properties.
This breakthrough has significant implications for cancer drug development, particularly in the context of HDAC inhibitors, a class of anti-cancer medicines that block histone deacetylases, enzymes regulating gene expression. The study's findings fill in the missing piece of the biological pathway for a chemically related compound, FR-901375, and demonstrate how bacteria use docking domains to enable combinatorial biosynthesis and produce multiple drug variants.
The research methodology was comprehensive, combining structural biology, biochemistry, genetics, and computational modeling. It involved bioinformatic searches, in vitro reconstitution experiments, AlphaFold computational modeling, carbene footprinting mass spectrometry, site-directed mutagenesis, gene deletion studies, and comparative analysis of biosynthetic gene clusters from multiple HDAC inhibitor-producing bacteria. This multi-faceted approach allowed the researchers to piece together the intricate puzzle of how bacteria naturally manufacture these powerful cancer drugs.
In conclusion, this discovery provides a new strategy for designing future cancer therapies, offering a more efficient and effective approach to drug development. By understanding and harnessing nature's "mix and match" system, scientists can now build upon this knowledge to create innovative cancer treatments, potentially revolutionizing the field of oncology.
